Late-Onset Hemorrhagic Cystitis in Children after Hematopoietic Stem Cell Transplantation for Thalassemia and Sickle Cell Anemia: A Prospective Evaluation of Polyoma (BK) Virus Infection and Treatment with Cidofovir

Javid Gaziev, Pierpaolo Paba, Roberto Miano, Stefano Germani, Pietro Sodani, Pierluigi Bove, Carlo Federico Perno, Marco Marziali, Cristiano Gallucci, Antonella Isgrò, Katia Paciaroni, Andrea Roveda, Maria Domenica Simone, Gioia De Angelis, Cecilia Alfieri, Guido Lucarelli

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

Little is known about late-onset hemorrhagic cystitis (HC) in children, its relationship to BK virus, and treatment with cidofovir (CDV) following hematopoietic stem cell transplantation (HSCT). We prospectively investigated BK virus reactivation in children who underwent HSCT from a matched related donor for thalassemia or sickle cell anemia following busulfan-cyclophosphamide-based conditioning regimens and analyzed risk factors for development of HC and its treatment with CDV. Grade 2-4 HC occurred in 30 patients with a cumulative incidence of 26% (95% confidence interval [CI] = 18%-34%). The cumulative incidences of BK viruria and viremia were 81% (95% CI = 69%-89%) and 28% (95% CI = 18%-40%), respectively. Multivariate analysis revealed that use of antithymocyte globulin (ATG) (hazard ratio [HR] = 10.5; P = .001), peak BK viruria >100,000 copies/mL (HR = 6.2; P = .004), and grade II-IV acute graft-versus-host disease (HR = 5.3; P = .007) were predictive factors for HC. Nineteen patients with HC were given CDV at 1.5 mg/kg/day 3 times a week, or 5 mg/kg/week. The median duration of therapy was 27 days (range, 21-180 days), and a median of 9 doses were given (range, 6-22). All patients had a complete clinical response (CCR), and 69% had a microbiological response at 4 weeks. Eleven patients with BK virus-related HC receiving supportive care also had CCR. The median duration of HC in these patients was similar to that in patients treated with CDV. None of the patients with HC cleared BK viruria when CCR was achieved. We conclude that late-onset HC is more prevalent in children with sustained high BK viruria who are treated with ATG or who develop graft-versus-host disease. Randomized clinical trials are urgently needed to better define the role of CDV in treating BK virus-related HC.

Original languageEnglish
Pages (from-to)662-671
Number of pages10
JournalBiology of Blood and Marrow Transplantation
Volume16
Issue number5
DOIs
Publication statusPublished - May 2010

Fingerprint

BK Virus
Polyomavirus
Cystitis
Thalassemia
Hematopoietic Stem Cell Transplantation
Sickle Cell Anemia
Virus Diseases
Therapeutics
Antilymphocyte Serum
Graft vs Host Disease
Confidence Intervals
cidofovir
Busulfan
Viremia
Incidence
Cyclophosphamide
Multivariate Analysis
Randomized Controlled Trials
Tissue Donors

Keywords

  • BK virus
  • Cidofovir
  • Hemoglobinopathies
  • Hemorrhagic cystitis
  • Stem cell transplantation

ASJC Scopus subject areas

  • Transplantation
  • Hematology

Cite this

Late-Onset Hemorrhagic Cystitis in Children after Hematopoietic Stem Cell Transplantation for Thalassemia and Sickle Cell Anemia : A Prospective Evaluation of Polyoma (BK) Virus Infection and Treatment with Cidofovir. / Gaziev, Javid; Paba, Pierpaolo; Miano, Roberto; Germani, Stefano; Sodani, Pietro; Bove, Pierluigi; Perno, Carlo Federico; Marziali, Marco; Gallucci, Cristiano; Isgrò, Antonella; Paciaroni, Katia; Roveda, Andrea; Simone, Maria Domenica; De Angelis, Gioia; Alfieri, Cecilia; Lucarelli, Guido.

In: Biology of Blood and Marrow Transplantation, Vol. 16, No. 5, 05.2010, p. 662-671.

Research output: Contribution to journalArticle

Gaziev, J, Paba, P, Miano, R, Germani, S, Sodani, P, Bove, P, Perno, CF, Marziali, M, Gallucci, C, Isgrò, A, Paciaroni, K, Roveda, A, Simone, MD, De Angelis, G, Alfieri, C & Lucarelli, G 2010, 'Late-Onset Hemorrhagic Cystitis in Children after Hematopoietic Stem Cell Transplantation for Thalassemia and Sickle Cell Anemia: A Prospective Evaluation of Polyoma (BK) Virus Infection and Treatment with Cidofovir', Biology of Blood and Marrow Transplantation, vol. 16, no. 5, pp. 662-671. https://doi.org/10.1016/j.bbmt.2009.12.009
Gaziev, Javid ; Paba, Pierpaolo ; Miano, Roberto ; Germani, Stefano ; Sodani, Pietro ; Bove, Pierluigi ; Perno, Carlo Federico ; Marziali, Marco ; Gallucci, Cristiano ; Isgrò, Antonella ; Paciaroni, Katia ; Roveda, Andrea ; Simone, Maria Domenica ; De Angelis, Gioia ; Alfieri, Cecilia ; Lucarelli, Guido. / Late-Onset Hemorrhagic Cystitis in Children after Hematopoietic Stem Cell Transplantation for Thalassemia and Sickle Cell Anemia : A Prospective Evaluation of Polyoma (BK) Virus Infection and Treatment with Cidofovir. In: Biology of Blood and Marrow Transplantation. 2010 ; Vol. 16, No. 5. pp. 662-671.
@article{dac6265cce3b42ab9e2293ceabab5f96,
title = "Late-Onset Hemorrhagic Cystitis in Children after Hematopoietic Stem Cell Transplantation for Thalassemia and Sickle Cell Anemia: A Prospective Evaluation of Polyoma (BK) Virus Infection and Treatment with Cidofovir",
abstract = "Little is known about late-onset hemorrhagic cystitis (HC) in children, its relationship to BK virus, and treatment with cidofovir (CDV) following hematopoietic stem cell transplantation (HSCT). We prospectively investigated BK virus reactivation in children who underwent HSCT from a matched related donor for thalassemia or sickle cell anemia following busulfan-cyclophosphamide-based conditioning regimens and analyzed risk factors for development of HC and its treatment with CDV. Grade 2-4 HC occurred in 30 patients with a cumulative incidence of 26{\%} (95{\%} confidence interval [CI] = 18{\%}-34{\%}). The cumulative incidences of BK viruria and viremia were 81{\%} (95{\%} CI = 69{\%}-89{\%}) and 28{\%} (95{\%} CI = 18{\%}-40{\%}), respectively. Multivariate analysis revealed that use of antithymocyte globulin (ATG) (hazard ratio [HR] = 10.5; P = .001), peak BK viruria >100,000 copies/mL (HR = 6.2; P = .004), and grade II-IV acute graft-versus-host disease (HR = 5.3; P = .007) were predictive factors for HC. Nineteen patients with HC were given CDV at 1.5 mg/kg/day 3 times a week, or 5 mg/kg/week. The median duration of therapy was 27 days (range, 21-180 days), and a median of 9 doses were given (range, 6-22). All patients had a complete clinical response (CCR), and 69{\%} had a microbiological response at 4 weeks. Eleven patients with BK virus-related HC receiving supportive care also had CCR. The median duration of HC in these patients was similar to that in patients treated with CDV. None of the patients with HC cleared BK viruria when CCR was achieved. We conclude that late-onset HC is more prevalent in children with sustained high BK viruria who are treated with ATG or who develop graft-versus-host disease. Randomized clinical trials are urgently needed to better define the role of CDV in treating BK virus-related HC.",
keywords = "BK virus, Cidofovir, Hemoglobinopathies, Hemorrhagic cystitis, Stem cell transplantation",
author = "Javid Gaziev and Pierpaolo Paba and Roberto Miano and Stefano Germani and Pietro Sodani and Pierluigi Bove and Perno, {Carlo Federico} and Marco Marziali and Cristiano Gallucci and Antonella Isgr{\`o} and Katia Paciaroni and Andrea Roveda and Simone, {Maria Domenica} and {De Angelis}, Gioia and Cecilia Alfieri and Guido Lucarelli",
year = "2010",
month = "5",
doi = "10.1016/j.bbmt.2009.12.009",
language = "English",
volume = "16",
pages = "662--671",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Late-Onset Hemorrhagic Cystitis in Children after Hematopoietic Stem Cell Transplantation for Thalassemia and Sickle Cell Anemia

T2 - A Prospective Evaluation of Polyoma (BK) Virus Infection and Treatment with Cidofovir

AU - Gaziev, Javid

AU - Paba, Pierpaolo

AU - Miano, Roberto

AU - Germani, Stefano

AU - Sodani, Pietro

AU - Bove, Pierluigi

AU - Perno, Carlo Federico

AU - Marziali, Marco

AU - Gallucci, Cristiano

AU - Isgrò, Antonella

AU - Paciaroni, Katia

AU - Roveda, Andrea

AU - Simone, Maria Domenica

AU - De Angelis, Gioia

AU - Alfieri, Cecilia

AU - Lucarelli, Guido

PY - 2010/5

Y1 - 2010/5

N2 - Little is known about late-onset hemorrhagic cystitis (HC) in children, its relationship to BK virus, and treatment with cidofovir (CDV) following hematopoietic stem cell transplantation (HSCT). We prospectively investigated BK virus reactivation in children who underwent HSCT from a matched related donor for thalassemia or sickle cell anemia following busulfan-cyclophosphamide-based conditioning regimens and analyzed risk factors for development of HC and its treatment with CDV. Grade 2-4 HC occurred in 30 patients with a cumulative incidence of 26% (95% confidence interval [CI] = 18%-34%). The cumulative incidences of BK viruria and viremia were 81% (95% CI = 69%-89%) and 28% (95% CI = 18%-40%), respectively. Multivariate analysis revealed that use of antithymocyte globulin (ATG) (hazard ratio [HR] = 10.5; P = .001), peak BK viruria >100,000 copies/mL (HR = 6.2; P = .004), and grade II-IV acute graft-versus-host disease (HR = 5.3; P = .007) were predictive factors for HC. Nineteen patients with HC were given CDV at 1.5 mg/kg/day 3 times a week, or 5 mg/kg/week. The median duration of therapy was 27 days (range, 21-180 days), and a median of 9 doses were given (range, 6-22). All patients had a complete clinical response (CCR), and 69% had a microbiological response at 4 weeks. Eleven patients with BK virus-related HC receiving supportive care also had CCR. The median duration of HC in these patients was similar to that in patients treated with CDV. None of the patients with HC cleared BK viruria when CCR was achieved. We conclude that late-onset HC is more prevalent in children with sustained high BK viruria who are treated with ATG or who develop graft-versus-host disease. Randomized clinical trials are urgently needed to better define the role of CDV in treating BK virus-related HC.

AB - Little is known about late-onset hemorrhagic cystitis (HC) in children, its relationship to BK virus, and treatment with cidofovir (CDV) following hematopoietic stem cell transplantation (HSCT). We prospectively investigated BK virus reactivation in children who underwent HSCT from a matched related donor for thalassemia or sickle cell anemia following busulfan-cyclophosphamide-based conditioning regimens and analyzed risk factors for development of HC and its treatment with CDV. Grade 2-4 HC occurred in 30 patients with a cumulative incidence of 26% (95% confidence interval [CI] = 18%-34%). The cumulative incidences of BK viruria and viremia were 81% (95% CI = 69%-89%) and 28% (95% CI = 18%-40%), respectively. Multivariate analysis revealed that use of antithymocyte globulin (ATG) (hazard ratio [HR] = 10.5; P = .001), peak BK viruria >100,000 copies/mL (HR = 6.2; P = .004), and grade II-IV acute graft-versus-host disease (HR = 5.3; P = .007) were predictive factors for HC. Nineteen patients with HC were given CDV at 1.5 mg/kg/day 3 times a week, or 5 mg/kg/week. The median duration of therapy was 27 days (range, 21-180 days), and a median of 9 doses were given (range, 6-22). All patients had a complete clinical response (CCR), and 69% had a microbiological response at 4 weeks. Eleven patients with BK virus-related HC receiving supportive care also had CCR. The median duration of HC in these patients was similar to that in patients treated with CDV. None of the patients with HC cleared BK viruria when CCR was achieved. We conclude that late-onset HC is more prevalent in children with sustained high BK viruria who are treated with ATG or who develop graft-versus-host disease. Randomized clinical trials are urgently needed to better define the role of CDV in treating BK virus-related HC.

KW - BK virus

KW - Cidofovir

KW - Hemoglobinopathies

KW - Hemorrhagic cystitis

KW - Stem cell transplantation

UR - http://www.scopus.com/inward/record.url?scp=77951208218&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951208218&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2009.12.009

DO - 10.1016/j.bbmt.2009.12.009

M3 - Article

C2 - 20026413

AN - SCOPUS:77951208218

VL - 16

SP - 662

EP - 671

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 5

ER -